New hope for rare sarcoma: two drugs face off in clinical trial
NCT ID NCT01391962
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase II trial tested two oral drugs, sunitinib and cediranib, in 34 people with metastatic alveolar soft part sarcoma (ASPS), a rare cancer that has no standard treatment. Participants were randomly assigned to one drug, and if their disease worsened, they could switch to the other. The goal was to see how often tumors shrank and how long they stayed controlled.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- sunitinib and cediranib (oral drugs that block blood vessel growth to tumors)
- What this could lead to
- If successful, this trial could identify an effective oral treatment option for a rare sarcoma that currently has no standard systemic therapy.
- What could go wrong
- This is a small phase II trial with only 34 participants, so results may not apply broadly. The drugs may cause side effects like fatigue, high blood pressure, or diarrhea, and tumors may still grow despite treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SARCOMA, ALVEOLAR SOFT PART are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States